Skip to content
OmniAb
  • About
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antibody Generation
      • Antigen Design
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmnidAb
      • OmniTaur
      • Bispecific Platforms
    • xPloration Screening
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • In Silico Technologies
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Financials
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Environment
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antibody Generation
      • Antigen Design
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmnidAb
      • OmniTaur
      • Bispecific Platforms
    • xPloration Screening
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • In Silico Technologies
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Financials
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Environment
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

Scientific Publications

Publications
Heavy chain-only antibodies with a stabilized human VH in transgenic chickens for therapeutic antibody discovery

mAbs, 2024
...
Read More

Publications
Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies

Journal of Immunology, 2024
...
Read More

Presentations
Deep Screening in Harmony with AI for Bispecific Antibody Discovery

PEGS Boston, 2024
...
Read More

Presentations
Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep

Antibody Engineering & Therapeutics US, 2023
...
Read More

Presentations
OmnidAb: Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding

Antibody Engineering & Therapeutics US, 2023
...
Read More

Presentations
Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding

PEGS Summit Europe, 2023
...
Read More

Presentations
Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep™

PEGS Boston, 2023
...
Read More

Presentations
Opening the Barn Door to Antibody Discovery

Antibody Engineering & Therapeutics Conference, 2022
...
Read More

Presentations
High-Specificity OmniAb Antibodies for Bispecific Applications; 2022 World Bispecific Conference

2022
...
Read More

Presentations
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose...

Cell Reports, 2022
...
Read More

Presentations
Discovery, Expression, and Characterization of Neutralizing Picobodies against SARS-CoV2

Antibody Engineering and Therapeutics, 2021
At 4-6 KD, “picobodies” represent the smallest known Ig-derived binding moiety capable of high affinity interactions with target proteins ...
Read More

Publications
Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for...

MAbs, 2021
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific ...
Read More
  • 1
  • 2
  • 3
  • 4
Loading...

About

  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

Contact | Privacy Policy | Disclaimer

© 2025 OmniAb, Inc. All rights reserved.